Thank you for correcting the text in this article. Your corrections improve Papers Past searches for everyone. See the latest corrections.

This article contains searchable text which was automatically generated and may contain errors. Join the community and correct any errors you spot to help us improve Papers Past.

Article image
Article image
Article image
Article image
Article image
Article image

Anti-cancer drug reported

A "scruffy little shrub” in Zululand, in the north-east comer of South Africa, has been found to be the world’s richest source of a new and powerful anti-cancer chemical. Jaap Boekkooi reports in the Johannesburg "Star” that the shrub, exclusive to South Africa, is classified under the comic designation genus putterlickia and is now the subject of a multimillion dollar study in the United States. As the world’s richest proved source of the anticancer agent Maytansine — now being clinically tested on terminal patients in the United States — it has

undergone long laboratory and animal testing. Describing the putterlickia, Mr Mike Wells, head of economic botany at the South African National Botanical Research Institute, said: “It is nothing to look at. It has insignificant flowers, but some of the berries and new leaves turn red. American scientists have been here a number of times to collect it and we have sent it to the United States in bulk.” The putterlickia is being tested against a wide range of cancers. Since testing is still in the experimental stages, years will be needed to prove its effectiveness and lack of side effects.

Permanent link to this item
Hononga pūmau ki tēnei tūemi

https://paperspast.natlib.govt.nz/newspapers/CHP19790409.2.92

Bibliographic details
Ngā taipitopito pukapuka

Press, 9 April 1979, Page 20

Word count
Tapeke kupu
192

Anti-cancer drug reported Press, 9 April 1979, Page 20

Anti-cancer drug reported Press, 9 April 1979, Page 20

Help

Log in or create a Papers Past website account

Use your Papers Past website account to correct newspaper text.

By creating and using this account you agree to our terms of use.

Log in with RealMe®

If you’ve used a RealMe login somewhere else, you can use it here too. If you don’t already have a username and password, just click Log in and you can choose to create one.


Log in again to continue your work

Your session has expired.

Log in again with RealMe®


Alert